Medimprint
Created in 2016
- BETA
Probably non active (C)
Several signals show that this company is not active anymore Social networks
52 525Activities
Technologies
Entity types
Location
5 Av. du Grand Sablon, 38700 La Tronche, France
La Tronche
France
Employees
Scale: 2-10
Estimated: 5
SIREN
446499345Engaged corporates
6
1 7Added in Motherbase
4 years, 8 months ago
deeptech Value proposition
Tissue fingerprinting as an innovation to better diagnose and treat brain diseases
Medimprint develops innovative, non-lesion medical devices, for clinical research in brain tumors and neurodegenerative diseases. Based on a new concept, “the brain tissue imprint”, Medimprint’s products are the new generation of companion medical devices for personalized and targeted therapies. The non-lesion feature of this concept allows an exclusive in vivo access to :
- Tumor heterogeneity
- Peritumoral regions
- Neurodegenerative regions for poly-omic molecular analyses.
Medimprint’s technology breakthrough relies on the integration of functionalized silicon chips to surgical stylet for atraumatic sampling. Through an original « hide and display» principle, the brief and specific interaction of silicon with brain tissue enables a simple apposition contact and the collection of spatially-oriented imprints.
The innocuity of these new medical devices has been recently validated in a phase 0 clinical trial.
neurodegenerative diseases, tissue imprint, molecular investigation, and tumor heterogeneityOriginal language
L'empreinte tissulaire comme innovation pour analyser et mieux traiter les tumeurs cérébrales et la maladie de Parkinson
Medimprint développe des dispositifs médicaux innovants non lésionnels, pour la recherche clinique sur les tumeurs cérébrales et les maladies neurodégénératives. Basés sur le nouveau concept "d'empreinte tissulaire cérébrale", les produits Medimprint sont la nouvelle génération de dispositifs médicaux compagnons pour des thérapies personnalisées et ciblées. La caractéristique non-lésionnelle de ce concept permet un accès à :
- Hétérogénéité tumorale
- Régions péritumorales
- Régions neurodégénératives pour les analyses moléculaires poly-omiques.
La rupture technologique de Medimprint repose sur l'intégration de puces de silicium fonctionnelles au stylet chirurgical pour l'échantillonnage non-traumatique. Grâce à un principe original de " hide and display ", l'interaction brève et spécifique du silicium avec le tissu cérébral permet un simple contact d'apposition et la collecte d'empreintes localisées dans l'espace.
L'innocuité de ces nouveaux dispositifs médicaux a récemment été validée dans un essai clinique de phase 0.
- http://www.medimprint.org
- Website is disabled or domain is for sale
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 PMT Public business cluster, French Cluster, Civic and Social Organizations | PMT Public business cluster, French Cluster, Civic and Social Organizations | Other 30 Sep 2021 | | |
 Bristol Myers Squibb Pharmaceutical, Pharmaceutical Manufacturing | Bristol Myers Squibb Pharmaceutical, Pharmaceutical Manufacturing | Other 24 Jul 2017 | | |
 Région Auvergne-Rhône-Alpes National and local authorities, Government Administration | Région Auvergne-Rhône-Alpes National and local authorities, Government Administration | Not capitalistic Partnership Event 4 Jul 2019 | | |
 Auvergne-Rhône-Alpes Entreprises National and local authorities, Business Consulting and Services | Auvergne-Rhône-Alpes Entreprises National and local authorities, Business Consulting and Services | Not capitalistic Partnership Event 4 Jul 2019 | | |
 Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Not capitalistic Partnership Event 4 Jul 2019 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Not capitalistic Partnership Not event 4 Jul 2019 | | |